Mopidamol

Drug Profile

Mopidamol

Alternative Names: OLX 102; RA 233; Rapenton

Latest Information Update: 27 Mar 2002

Price : $50

At a glance

  • Originator Boehringer Ingelheim Pharma KG
  • Developer Antigenics; Boehringer Ingelheim Pharma KG
  • Class Pyrimidines; Small molecules
  • Mechanism of Action Immunostimulants; Phosphoric diester hydrolase inhibitors; Thromboxane receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Cancer metastases
  • Discontinued Non-small cell lung cancer; Ovarian cancer; Thrombosis

Most Recent Events

  • 27 Mar 2002 Launched for Cancer metastases in Germany (IV)
  • 07 Feb 2001 No-Development-Reported for Cancer metastases in Germany (IV)
  • 12 Jan 2000 Discontinued-Preclinical for Thrombosis in Europe (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top